Otamixaban

Drug Profile

Otamixaban

Alternative Names: 0673; FXV 673; RPR 130673; XRP 0673; XRP0673A

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antithrombotics; Benzamidines; Butyric acids; Cyclic N oxides; Esters; Pyridines; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes

Most Recent Events

  • 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Argentina (IV)
  • 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Australia (IV)
  • 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top